Samsung Biologics’ youngest female executives.

<이미지를 클릭하시면 크게 보실 수 있습니다>

Samsung Biologics and Samsung Bioepis announced their 2026 executive promotions on Tuesday, highlighting new leaders in production, process development, technology transfer, clinical operations, and strategy to strengthen global competitiveness next year. Notably, Samsung Biologics appointed two of its youngest-ever female executives.

At Samsung Biologics, six executives were promoted, including two vice presidents and four senior managers. Among them, Kim Hee-jeong was promoted to vice president in her 40s, while Ahn So-yeon, in her 30s, became a senior manager—making both the youngest female executives in the company’s history.

Kim was recognized for stabilizing the drug substance (DS) production system amid expanding capacity and ramping up new plants, significantly enhancing the company’s manufacturing efficiency. Ahn led process and scheduling optimization following the completion of Plant 4, achieving early full-scale operation and establishing a stable pharmaceutical production base.

Jung Hyung-nam was promoted to vice president for his leadership in antibody-drug conjugate (ADC) projects, launching new services and advancing in-house antibody technologies to strengthen contract development (CDO) competitiveness. Yoo Dong-seon improved tech-transfer capabilities through manufacturing science and technology (MSAT) process optimization, while Cha Young-pil and Hwang Jun-ho were recognized for enhancing process efficiency through advanced MES and operations systems.

Samsung Bioepis also promoted six executives, including two vice presidents and four senior managers. Shin Dong-hoon, a medical doctor, was promoted to vice president for leading biosimilar clinical design and regulatory strategy, while Shin Ji-eun, a specialist in process development and technology transfer, was recognized for optimizing production processes and securing new partners.

Among senior managers, Jung Eui-han, born in 1987, became the youngest executive at Bioepis. He expanded product approvals across new markets, increasing revenue potential and reducing development costs and timelines. Son Sung-hun oversaw global IP litigation and legal support, Ahn So-shin established preclinical development systems, and Lee Nam-hoon contributed to strategic planning and supply chain management (SCM), supporting the company’s transition to a holding structure.

Both firms stated that they would “continue to strengthen trust with global clients, secure long-term technological leadership, and drive sustainable growth as global biopharmaceutical leaders.”